MOTS-c: what it is and what the research actually shows

In “It’s Official: 7 Life-Changing Peptides are BACK.”, Dr. Alex Tatem discusses MOTS-c. What he says, in short:

• He lists MOTS-c among the longevity, sleep and nootropic peptide group, describing it simply as pitched as an exercise mimetic.
• He says MOTS-c was one of the 19 peptides bumped from category 1 to category 2 in the FDA's abrupt September 29, 2023 list change.
• He notes MOTS-c is one of seven peptides scheduled for day one of the FDA's Pharmacy Compounding Advisory Committee hearing on July 23 to 24, 2026, alongside BPC-157, KPV and TB-500.
• He cautions that even a maximally favorable PCAC outcome for MOTS-c would not mean FDA approval or proven safety and effectiveness, just renewed compounding eligibility, with real pharmacy access likely not arriving until late 2026 or into 2027.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.

In “Every Popular Peptide Ranked | GLP-1, Growth Hormone, HCG, NAD+, IGF-1, Peptide Tier List”, Dr. Alex Tatem discusses MOTS-c. What he says, in short:

• He describes MOTS-c as derived from mitochondrial DNA and theorized to raise basal metabolism and fat burning by boosting mitochondrial activity.
• He notes users report feeling more energetic, but says that effect is also seen with placebo, and there is no good human clinical data controlling for that.
• He calls it interesting but not competitive with better options, giving it a D tier ranking.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.

In “Dr. Explains - The Truths about Mots-C Nobody is Talking About”, Dr. Ashley Froese discusses MOTS-c. What she says, in short:

• She describes MOTS-c as a 16 amino acid peptide made from mitochondrial DNA, discovered in 2015, whose production spikes with exercise, fasting, low oxygen, and thermal extremes.
• She says it activates AMPK, increasing insulin sensitivity and fat oxidation, prompting cells to pull sugar from the blood, burn stagnant fatty acids, and build new mitochondria, and she credits it with improving muscular endurance.
• She cites mouse studies where MOTS-c prevented and reversed diet induced obesity and insulin resistance, reversed age related physical decline in old mice, and reduced heart wall thickening by 8% in diabetic rats.
• She cites a mouse menopause model, ovaries removed, where MOTS-c slowed bone breakdown and triggered new bone formation, which she says is why it might eventually be studied for osteoporosis.
• She cites human research linking higher natural MOTS-c to lower myostatin, meaning less limit on muscle growth, lower MOTS-c levels in women with PCOS and severe sleep apnea, and low MOTS-c in ovarian cancer cells, where adding it back slowed cancer progression in that research.
• She warns MOTS-c causes more injection site welts than other peptides she has seen, can make some people jittery, anxious, or cause blood sugar crashes, and flags a theoretical concern about feeding cancer cells plus a lack of long term human safety data.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

In “The Mitochondria Repair Peptide Your Doctor Has Never Heard About”, Dr. Ashley Froese discusses MOTS-c. What she says, in short:

• She contrasts MOTS-c with this video's main topic, SS-31, saying MOTS-c forces the body down the pathway of making new mitochondria, while SS-31 stabilizes the mitochondria that already exist.
• She pushes back on the popular internet claim that people must use SS-31 before MOTS-c, saying that isn't necessarily true.
• She says a calculated approach could make sense, such as stabilizing mitochondria with SS-31 first and boosting with MOTS-c later, or using urolithin A to clear out failing mitochondria before stabilizing and boosting, though she calls this her own opinion and not a precise science.
• She mentions she has a separate video specifically explaining how MOTS-c works, for anyone wanting more detail.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

In “The FDA Is About to Decide the Future of Peptides: BPC-157, TB-500, KPV, & MOTS-C”, Dr. Ashley Froese discusses MOTS-c. What she says, in short:

• She says the FDA is reviewing it for obesity and osteoporosis.
• She says it lives naturally in the body and is made more when doing hard things like exercise, cold plunging, or fasting.
• She says it activates AMPK, which increases mitochondrial biogenesis, mobilizes fatty acids, increases angiogenesis, increases insulin sensitivity, and increases muscular fiber endurance, calling it exercise in a vial.
• She says most people who use it are not using it for obesity or osteoporosis, but for metabolic improvements, as an exercise mimetic, a pre-workout peptide, or sometimes fat loss.
• She cites a rat study where high fat diet rats given the peptide avoided becoming obese, and another group of obese rats had their obesity reversed.
• For osteoporosis, she explains that menopause removes estrogen's protection over mitochondria, and cites a rat study showing the peptide reversing that bone loss problem.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

In “Real Doctor: If I Started Peptides Today, I'd Do THIS (The Ultimate Peptide Roadmap)”, Dr. Ashley Froese discusses MOTS-c. What she says, in short:

• In her roadmap, she introduces MOTS-c early, alongside retatrutide and tesamorelin, as part of a patient's weight loss plan.
• She frames it primarily as a mitochondrial peptide first, saying it encourages the body to make more mitochondria and improves insulin sensitivity, with weight loss as a side effect.
• Later in the energy step, she says pairing MOTS-c with SS-31 is reasonable, describing SS-31 as repairing the engine while MOTS-c builds more of them.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

In “Stack Retatrutide & These 2 Peptides to STOP The Aging Clock (GHK-Cu, MOTS-c)”, Dr. Jones, DC discusses MOTS-c. What he says, in short:

• He calls MOTS-c a mitochondrial derived peptide that the body makes, and assigns it the mitochondrial hand of what he calls the three-handed aging clock.
• He states flatly and repeats that MOTS-c is not an energy peptide, and says he does not recommend it to patients who ask what to take for energy even though he could sell it to them.
• He says it revs an engine you already have rather than manufacturing energy, so revving a damaged mitochondrial network harder may hurt rather than help.
• He gives a clinic anecdote of a 38-year-old patient who felt worse three weeks in with brain fog, crashes and slower recovery, and who tolerated it cleanly after running SS-31 first.
• He says sequencing is not optional and that the do-it-yourself mistake is picking MOTS-c first off a list without asking whether the engine is ready for it.
• He lists four things he wants locked in before this kind of stack, naming insulin resistance work, a protein floor, sleep, and full foundation labs rather than a basic annual panel.

MOTS-c is not an energy peptide. Read that again. MOTS-c is not an energy peptide.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “The ULTIMATE Peptide Stack For Fat Loss & Metabolic Flexibility! | Dr. Jones DC”, Dr. Jones, DC discusses MOTS-c. What he says, in short:

• He calls MOTS-c a mitochondrial derived peptide released in response to cellular and metabolic stress, which is why he says the exercise mimetic label is literal rather than marketing.
• He lists the mechanisms he took from the data as mitochondrial biogenesis, cristae formation increasing surface area for the electron transport chain, and mitophagy recycling damaged machinery.
• He notes there are studies looking at MOTS-c as a potential aid in disease prevention, framing that as fascinating rather than settled.
• He is explicit that you produce MOTS-c naturally with high-intensity exercise, and says he has to say that before recommending anyone buy it.
• He states a protocol of a 10 mg single-use vial injected once a week for 8 weeks as a solid cycle, calling that the minimum he has seen in the data.
• He says some people suggest that the more dysregulated, insulin resistant or inflamed you are, the more you might do better increasing frequency to two or three times a week for the first two weeks before tapering to weekly.

usually 10 mg a bottle and you inject 10 mg one time a week for 8 weeks is a solid cycle

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “Doctor Explains How the FDA Vote Changes BPC-157, TB-500, KPV & MOTS-c”, Dr. Jones, DC discusses MOTS-c. What he says, in short:

• He says MOTS-c was one of four compounds heard and voted on in a single day by an FDA advisory committee, and stresses that approval was never on the table.
• He explains the actual question was whether to recommend placing the substance on the 503A bulk list of ingredients compounding pharmacies may work from, and that the committee only advises.
• He says the FDA objection to MOTS-c was that the nomination proposed an injection at a specific concentration without ever specifying which chemical form was meant, so a dose could not be evaluated.
• He notes every one of these compounds was voted on twice because the paperwork did not establish what the single substance actually was.
• He emphasizes that none of the objections raised were findings that the compounds hurt people, and characterizes the barrier as documentation, naming and manufacturing rather than safety.
• He relays third-party testing presented to the committee showing gray market products coming in stronger than labeled rather than watered down, while noting the presenter sells the domestic alternative and did not disclose his methodology.

The nomination proposed an injection at a specific concentration, and it never specified which chemical form it meant.

Not one of them is a finding that these compounds hurt people.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.